NanoVibronix, now under new leadership since June 2025, has announced a strategic shift following a thorough review of its operations and market opportunities. The company has identified the ENvue feeding-tube placement system as its primary growth platform. ENvue, which was integrated into NanoVibronix earlier this year, is FDA-cleared and already enhancing clinical procedures in U.S. hospitals by providing real-time anatomical navigation for enteral-tube placements. With the enteral feeding devices market in the U.S. expected to reach $1.8 billion by 2030, NanoVibronix sees significant growth potential. The company plans to rebrand as ENvue Medical, reflecting its focus on precision enteral access and technology-driven growth. As part of this new direction, NanoVibronix is considering strategic alternatives for its legacy technologies, such as partnerships or divestitures, to concentrate on its core strengths in enteral navigation.
Is NanoVibronix set to rebrand and explore new strategies for its legacy technologies?
